CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: May 12, 2020
Result type: Reports
Project Number: SR0525-000
Product Line: Reimbursement Review

Generic Name: nusinersen

Brand Name: Spinraza

Manufacturer: Biogen Canada Inc.

Therapeutic Area: Spinal Muscular Atrophy

Indications: Spinal Muscular Atrophy

Submission Type: Initial

Project Status: Complete

Biosimilar: No

Date Recommendation Issued: December 22, 2017

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule: Schedule A

Request for Resubmission: Eligible (May 24, 2018)

Key Milestones2

Call for patient input postedJune 01, 2017
Patient group input closedJuly 21, 2017

- Patient input submission received

Patient input summary sent for review to patient input groupsJuly 27, 2017
Patient group comments on input summary closedAugust 04, 2017

- Patient input summary feedback received

Submission receivedJune 28, 2017
Submission acceptedJuly 13, 2017
Review initiatedJuly 14, 2017
Draft CADTH review report(s) sent to sponsorOctober 02, 2017
Comments from sponsor on draft CADTH review report(s) receivedOctober 12, 2017
Redaction requests from sponsor on draft CADTH review report(s) receivedOctober 19, 2017
CADTH review team's comments on draft CADTH review report(s) sent to sponsorNovember 03, 2017
Canadian Drug Expert Committee (CDEC) meetingNovember 15, 2017
CDEC recommendation & redacted CADTH review report(s) sent to sponsor and drug plansNovember 29, 2017
Embargo period ended and validation of redacted CADTH review report(s) receivedDecember 13, 2017
CDEC Final Recommendation issued to sponsor and drug plansDecember 20, 2017
CDEC Final Recommendation postedDecember 22, 2017
Final CADTH review report(s) and patient input postedJanuary 10, 2018